{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:58Z","timestamp":1786987018901,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["110534"],"award-info":[{"award-number":["110534"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.cllc.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T00:01:16Z","timestamp":1521244876000},"page":"e441-e463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["MET Expression in Advanced Non\u2013Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Henning","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Savvidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaid","family":"Darwiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried E.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Skiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Westerwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Nensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wiesweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.03.010_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","article-title":"The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance","volume":"142","author":"Maroun","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cllc.2018.03.010_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cllc.2018.03.010_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.bjc.6603884","article-title":"Downstream signalling and specific inhibition of c-MET\/HGF pathway in small cell lung cancer: implications for tumour invasion","volume":"97","author":"Ma","year":"2007","journal-title":"Br J Cancer"},{"issue":"1 suppl","key":"10.1016\/j.cllc.2018.03.010_bib4","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.prp.2016.05.006","article-title":"Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non\u2013small-cell lung cancers: a meta-analysis","volume":"212","author":"Pyo","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.cllc.2018.03.010_bib6","doi-asserted-by":"crossref","first-page":"e107677","DOI":"10.1371\/journal.pone.0107677","article-title":"MET gene copy number predicts worse overall survival in patients with non\u2013small-cell lung cancer (NSCLC); a systematic review and meta-analysis","volume":"9","author":"Dimou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2018.03.010_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib8","first-page":"817297","article-title":"Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients","volume":"2012","author":"Lin","year":"2012","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.cllc.2018.03.010_bib9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.03.010_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.03.010_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non\u2013small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.03.010_bib12","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2014.32.15_suppl.8001","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non\u2013small-cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.03.010_bib13","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/jco.2014.32.15_suppl.8017","article-title":"Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase lb\/ll study","volume":"32","author":"Wu","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.03.010_bib14","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2016.34.15_suppl.9067","article-title":"Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non\u2013small-cell lung cancer (NSCLC)","volume":"34","author":"Schuler","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12 Suppl 2","key":"10.1016\/j.cllc.2018.03.010_bib15","article-title":"Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non\u2013small-cell lung cancer, and hepatocellular carcinoma","volume":"14","author":"Banck","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2018.03.010_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non\u2013small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib17","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","article-title":"Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non\u2013Small-Cell Lung cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1535-7163.MCT-16-0472","article-title":"MET in lung cancer: biomarker selection based on scientific rationale","volume":"16","author":"Salgia","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2018.03.010_bib19","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.ejca.2013.06.014","article-title":"Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a comprehensive cancer center","volume":"49","author":"Wiesweg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2018.03.010_bib20","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2015"},{"key":"10.1016\/j.cllc.2018.03.010_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2016.08.137","article-title":"High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer","volume":"12","author":"Wiesweg","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2015.02.002","article-title":"HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas","volume":"88","author":"Reis","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.03.010_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2016"},{"key":"10.1016\/j.cllc.2018.03.010_bib24","author":"Kassambara"},{"key":"10.1016\/j.cllc.2018.03.010_bib25","series-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2009"},{"key":"10.1016\/j.cllc.2018.03.010_bib26","series-title":"Bayesian Survival Analysis","author":"Ibrahim","year":"2001"},{"key":"10.1016\/j.cllc.2018.03.010_bib27","series-title":"Encyclopedia of Biostatistics","article-title":"Bayesian survival analysis","author":"Ibrahim","year":"2005"},{"key":"10.1016\/j.cllc.2018.03.010_bib28","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.7717\/peerj-cs.55","article-title":"Probabilistic programming in Python using PyMC3","volume":"2","author":"Salvatier","year":"2016","journal-title":"Peer J Comput Sci"},{"issue":"suppl C","key":"10.1016\/j.cllc.2018.03.010_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jspi.2013.09.014","article-title":"Decision-theoretic justifications for Bayesian hypothesis testing using credible sets","volume":"146","author":"Thulin","year":"2014","journal-title":"J\u00a0Stat Plan Inference"},{"key":"10.1016\/j.cllc.2018.03.010_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/e1040099","article-title":"Evidence and credibility: full Bayesian significance test for precise hypotheses","volume":"1","author":"De Bragan\u00e7a Pereira","year":"1999","journal-title":"Entropy"},{"key":"10.1016\/j.cllc.2018.03.010_bib31","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jtho.2016.01.017","article-title":"Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation\u2013positive lung adenocarcinoma","volume":"11","author":"Shea","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2016.09.116","article-title":"Responses to crizotinib can occur in high-level MET-amplified non\u2013small-cell lung cancer independent of MET Exon 14 Alterations","volume":"12","author":"Caparica","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cllc.2018.03.010_bib34","first-page":"9","article-title":"Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non\u2013small-cell lung cancer","volume":"7","author":"Puri","year":"2008","journal-title":"J\u00a0Carcinog"},{"key":"10.1016\/j.cllc.2018.03.010_bib35","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jtho.2016.02.021","article-title":"Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification","volume":"11","author":"Gainor","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cllc.2018.03.010_bib37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1055-9965.EPI-10-1080","article-title":"MET expression and amplification in patients with localized gastric cancer","volume":"20","author":"Janjigian","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cllc.2018.03.010_bib38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/JTO.0b013e318240ca0d","article-title":"Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non\u2013small-cell lung cancer","volume":"7","author":"Dziadziuszko","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.cllc.2018.03.010_bib40","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"Moss\u00e9","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.03.010_bib41","first-page":"37","article-title":"The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer","volume":"1795","author":"Acquaviva","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cllc.2018.03.010_bib42","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl C","key":"10.1016\/j.cllc.2018.03.010_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.03.010_bib44","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non\u2013small-cell lung cancer","volume":"7","author":"Gou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2018.03.010_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small-cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cllc.2018.03.010_bib47","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","article-title":"Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression","volume":"290","author":"Balan","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cllc.2018.03.010_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2018.03.010_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2015-0510","article-title":"MET exon 14 skipping in non\u2013small-cell lung cancer","volume":"21","author":"Heist","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.03.010_bib51","doi-asserted-by":"crossref","first-page":"41691","DOI":"10.18632\/oncotarget.9541","article-title":"MET exon 14 skipping defines a unique molecular class of non\u2013small-cell lung cancer","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.03.010_bib52","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2017.35.15_suppl.8512","article-title":"PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non\u2013small-cell lung cancers (NSCLC)","volume":"35","author":"Sabari","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.03.010_bib53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non\u2013small-cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418300524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418300524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:07:04Z","timestamp":1761505624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418300524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1525730418300524"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.03.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET Expression in Advanced Non\u2013Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}